Last Price
3.11
Today's Change
-0.035 (1.11%)
Day's Change
3.09 - 3.22
Trading Volume
25,851
Market Cap
37 Million
Shares Outstanding
12 Million
Avg Volume
382,325
Avg Price (50 Days)
8.21
Avg Price (200 Days)
27.98
PE Ratio
-0.69
EPS
-4.51
Earnings Announcement
11-Mar-2025
Previous Close
3.15
Open
3.10
Day's Range
3.095 - 3.22
Year Range
2.9 - 53.79
Trading Volume
25,851
1 Day Change
-1.11%
5 Day Change
-5.03%
1 Month Change
-6.74%
3 Month Change
-93.12%
6 Month Change
-90.95%
Ytd Change
-9.71%
1 Year Change
-75.06%
3 Year Change
-95.60%
5 Year Change
-99.06%
10 Year Change
-99.07%
Max Change
-99.07%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.